Mostrar el registro sencillo del ítem
dc.contributor.author
Liberman, Federico
dc.contributor.author
Elgart, Jorge Federico
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Strusberg, Ingrid
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2021-01-11T15:45:37Z
dc.date.issued
2019-12
dc.identifier.citation
Liberman, Federico; Elgart, Jorge Federico; Strusberg, Ingrid; Economic Benefit of Sponsored Controlled Clinical Trials: The Avoidable Cost in Drugs for the Treatment of Rheumatoid Arthritis; Elsevier Inc; Value in Health Regional Issues; 20; 12-2019; 7-11
dc.identifier.issn
2212-1102
dc.identifier.uri
http://hdl.handle.net/11336/122244
dc.description.abstract
Objectives: To estimate the following: (1) the avoidable cost of biologic (bDMARDs) and conventional synthetic Rheumatoid Arthritis (RA) modifying antirheumatic drugs (csDMARDs) during controlled clinical trials (CCTs), their extension period, and for bDMARDs in post study drug programs; and (2) to evaluate the impact on health insurances. Methods: We analyzed 13 CCTs (233 patients) that evaluated bDMARDs. Avoidable cost was what the health insurance should have paid if the patient had not received the medication from the CCT sponsor and was estimated with a micro-costing approach (bottom-up method). Results were expressed as mean ± standard deviation (SD) or percentages. Approved by the Ethics Committee. Results: Mean age was 50.62 SD 11.8 years, 84% were women, 72% (n ¼ 166) had health insurance. The mean annual cost of bDMARDs was US$ 30 567.40 while the cost for csDMARDs was US$ 104.90 during the CCTs. The mean annual cost in extension periods and post study drug programs for bDMARDs was US$ 36 016.20 and for csDMARs during the extension period was US$ 81.70. The avoidable cost for public health insurances exceeded one million dollars per year. Conclusion: This work describes for the first time in Argentina the significant economic benefit that may represent for RA patients’ health insurances the participation in CCTs with bDMARDs. It shows that during the execution of the CCT, its extension periods, or post study access programs, while medication provision is guaranteed, the economic burden imposed by the treatment of the RA is relieved.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Elsevier Inc
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
AVOIDABLE COSTS
dc.subject
CONTROLLED CLINICAL TRIALS
dc.subject.classification
Políticas y Servicios de Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Ciencias de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Economic Benefit of Sponsored Controlled Clinical Trials: The Avoidable Cost in Drugs for the Treatment of Rheumatoid Arthritis
dc.title
Beneficio económico de los ensayos clínicos controlados patrocinados: El gasto evitable en medicamentos para el tratamiento de la artritis reumatoidea
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2020-11-20T17:17:50Z
dc.identifier.eissn
2212-1099
dc.journal.volume
20
dc.journal.pagination
7-11
dc.journal.pais
Estados Unidos
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.description.fil
Fil: Liberman, Federico. Universidad Nacional de Córdoba. Facultad de Medicina; Argentina
dc.description.fil
Fil: Elgart, Jorge Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Endocrinología Experimental y Aplicada. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Centro de Endocrinología Experimental y Aplicada; Argentina
dc.description.fil
Fil: Strusberg, Ingrid. Universidad Nacional de Córdoba. Facultad de Medicina; Argentina. Instituto Médico Strusberg; Argentina
dc.journal.title
Value in Health Regional Issues
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.vhri.2018.10.007
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S2212109918303595
Archivos asociados